- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
HBV & HDV Update at Paris HBV Meeting
HBV Meeting Paris: Strong decline of intrahepatic HDV markers and signs of liver inflammation after 48 weeks of treatment with Bulevirtide in chronic hepatitis D patients: Combined intrahepatic results from the clinical trials MYR203 and MYR301 - (09/26/22)
HBV Drug Pipeline - at HBV Intl Meeting 2022 Paris - (09/26/22)
HBV Meeting Paris: Replicor expands efficacy and safety envelope in decompensated cirrhosis with compassionate use of subcutaneous REP 2139-Mg - (09/26/22)
HBV Meeting Paris: Dose-Dependent Durability of Hepatitis B Surface Antigen Reductions Following Administration of a Single Dose of VIR-3434, an Investigational, Neutralizing Vaccinal Monoclonal Antibody - (09/26/22)
VIR-2218 Plus VIR-3434 Combination Therapy Reduces Hepatitis B Virus Surface Antigen Levels In Vivo - (09/26/22)
Pharmacokinetics of ATI-1428, a Novel Ultra-potent Capsid Assembly Modulator - (09/26/22)
HBV Meeting Paris: Next-generation core inhibitors demonstrate increased potency and distinct biochemical properties compared to first-generation core inhibitors - (09/26/22)
HBV Meeting Paris: Combination treatment with AB-101, a small-molecule PD-L1 Inhibitor, and an HBV-targeting GalNAc-siRNA increases HBV-specific immune responses in a chronic Hepatitis B infection mouse model - (09/26/22) |
|